-
After Alkermes' makeover, CEO Richard Pops touts its pipeline program and rare biotech model
13 Jan 2025 17:04 GMT
… business underneath it,” Richard Pops, Alkermes’ chairman and CEO, said … in 2023, when Alkermes spun off its cancer business into an … 39;s lead pipeline asset, ALKS 2680, is in a phase … Pops said.
Until ALKS 2680 hits the market, Alkermes will generate much …
-
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
14 Oct 2024 20:45 GMT
… Relative Strength (RS) Rating for Alkermes (ALKS) moved up into a new … Market?
Ireland-based Alkermes develops treatments for cancer and neurodegenerative diseases (conditions … the nervous system).
Watchlist candidate Alkermes stock is trying to complete …
-
Alkermes plc (NASDAQ:ALKS) Shares Purchased by Arizona State Retirement System
05 Feb 2024 11:55 GMT
… its holdings in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 2 … development for neurological disorders and cancer.
Featured Articles
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …
-
Alkermes plc (NASDAQ:ALKS) Stock Holdings Boosted by Los Angeles Capital Management LLC
03 Feb 2024 10:35 GMT
… its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 120 … development for neurological disorders and cancer.
See Also
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …
-
Raymond James & Associates Buys 6,510 Shares of Alkermes plc (NASDAQ:ALKS)
01 Feb 2024 09:36 GMT
… its holdings in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 32 … development for neurological disorders and cancer.
See Also
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …
-
Alkermes plc Expected to Post FY2024 Earnings of $2.47 Per Share (NASDAQ:ALKS)
01 Feb 2024 09:42 GMT
Alkermes plc (NASDAQ:ALKS – Free Report) – Equities research analysts … by institutional investors.
Alkermes Company Profile
(Get Free Report)
Alkermes plc, a biopharmaceutical … disorders and cancer.
Read More
Receive News & Ratings for Alkermes Daily …
-
Alkermes plc (NASDAQ:ALKS) Short Interest Down 5.6% in January
01 Feb 2024 09:35 GMT
Alkermes plc (NASDAQ:ALKS – Get Free Report) saw a … Latest Analysis on Alkermes
About Alkermes
(Get Free Report)
Alkermes plc, a biopharmaceutical company … disorders and cancer.
Recommended Stories
Receive News & Ratings for Alkermes Daily …
-
California Public Employees Retirement System Raises Stake in Alkermes plc (NASDAQ:ALKS)
25 Jan 2024 11:44 GMT
… System boosted its holdings in Alkermes plc (NASDAQ:ALKS – Free Report) by 13 … development for neurological disorders and cancer.
Further Reading
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …
-
EFG Asset Management North America Corp. Has $1.57 Million Holdings in Alkermes plc (NASDAQ:ALKS)
22 Jan 2024 16:22 GMT
… Corp. lessened its holdings in Alkermes plc (NASDAQ:ALKS – Free Report) by 8 … Our Latest Report on Alkermes
Alkermes Profile
(Free Report)
Alkermes plc, a biopharmaceutical company … disorders and cancer.
Read More
Receive News & Ratings for Alkermes Daily …
-
TD Asset Management Inc Buys Shares of 56,000 Alkermes plc (NASDAQ:ALKS)
21 Jan 2024 11:31 GMT
… bought a new stake in Alkermes plc (NASDAQ:ALKS – Free Report) during the … development for neurological disorders and cancer.
See Also
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …
About
© 1995-2025